Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Busines...
March 01 2021 - 4:05PM
Corcept Therapeutics Incorporated (NASDAQ: CORT), a
commercial-stage company engaged in the discovery and development
of drugs to treat severe metabolic, oncologic and psychiatric
disorders by modulating the effects of the hormone cortisol, today
announced that Atabak Mokari has joined the company as Chief
Financial Officer. Charles Robb, who has been Corcept’s CFO since
September 2011, has assumed the role of Chief Business Officer.
“Atabak’s talent and broad experience make him a
welcome addition to our executive team,” said Joseph K. Belanoff,
MD, Corcept’s Chief Executive Officer. “Further, his arrival will
allow Charlie to focus on the significant administrative and
operational tasks we will face in 2021 and beyond.”
Atabak Mokari has nearly 20 years leadership
experience in life sciences and healthcare finance. From 2018 to
2020, he was Chief Financial Officer and Vice President of
Corporate Development at Bellicum Pharmaceuticals, Inc. He served
in the same capacity from 2016 to 2018 at medical device
manufacturer IRIDEX. Mr. Mokari was a director at Wells Fargo
Securities LLC’s healthcare investment banking group from 2013 to
2016, at UBS’s healthcare investment banking group from 2009 to
2013 and at Credit Suisse’s healthcare investment banking group
from 2005 to 2009. Prior to that, he was a member of the business
development team at Forest Laboratories, a pharmaceutical company,
and an analyst at the private equity firm Olympus Partners and the
investment banking firm Bowles Hollowell Conner & Co. Mr.
Mokari earned an MBA from The Tuck School of Business at Dartmouth
and a B.S. in Chemistry and Biology from Duke University.
About Corcept Therapeutics
Corcept is a commercial-stage company engaged in
the discovery and development of drugs to treat severe metabolic,
oncologic and psychiatric disorders by modulating the effects of
the hormone cortisol. Korlym® was the first drug approved by the
U.S. Food and Drug Administration for patients with Cushing’s
syndrome. Corcept has discovered a large portfolio of proprietary
compounds that selectively modulate the effects of cortisol. The
company owns extensive United States and foreign intellectual
property covering the composition of its selective cortisol
modulators and the use of cortisol modulators to treat a variety of
serious disorders.
CONTACT:Christopher S. James,
MDDirector, Investor RelationsCorcept
Therapeutics650-684-8725cjames@corcept.com www.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024